Substance Addictions & Their Brain Reward Systems: Drugs, Alcohol & Nicotine
Convener’s Introduction: Why This Science Matters?
Wouldn't it be wonderful to attribute our compulsion for addictive damaging activities, such as over-drinking, smoking or taking illicit drugs, wholly to our genetic make-up? Then we could blame our parents for everything! We know it is bad for us, but we still do it. Why?
Clinical Trial and Error: Beauty and the Beast
Organised by SciCom
Co-Organised by: Thomas Hartung, Johns Hopkins University
14 – 18 February, 2013, Boston USA
Annual Meeting, American Association for the Advancement of Science (AAAS):
The Beauty and the Benefits of Science
Independent clinical trials are fundamental to improving the results, safety, and cost-effectiveness of health care. Because of costs, the scope of these trials is often limited to new products. Important clinical interventions, surgery, physiotherapy, and rehabilitation are of less interest to commercial sponsors seeking primarily drug and device authorization. Whereas investigator-driven studies now find support in the United States and European Union, they cannot match the resources available for commercial clinical trials. Public and charitable funding typically backs health care–orientated trials independently of manufacturers, but is often much smaller in size. Results matter. When we do get such new evidence, it allows us to look back: how good was the preclinical research to start with? While evidence-based medicine is the health care imperative of the 21st century, it remains difficult to generate the evidence base for pressing public health challenges. This session unites key stages and world authorities in the clinical trials process to explain why and what must change. With expertise on leading animal and human studies to end products, speakers will provide new insights into how clinical trials are conducted. Their common cause will be to argue that greater international cooperation and standards are required. That said, effective communication of clinical and societal benefits must be better coordinated to citizens, patients, health-care professionals, researchers, policy-makers, and society as a whole.
27th European PV Solar Energy Conference & Exhibition
27th EU PVSEC - Post Event Report
Industry, Research, Finance and Politics give a strengthened Mandate to PV
“Photovoltaic solar energy is here to stay but is now at a tipping point. Electricity business leaders, investors, innovators, regulators and especially policy-makers must join forces and push ahead with an inevitable paradigm shift in the way electricity is produced, sold, transported and distributed", Conference General Chairman Dr. Stefan Nowak, Chairman IEA PVPS, International Energy Agency Photovoltaic Power Systems Programme, concluded after this year's 27th European Photovoltaic Solar Energy Conference and Exhibition at the Messe Frankfurt fairground.
Euroscience Open Forum 2012
Organised by SciCom on behalf of the Government of South Africa
- Dublin, Saturday 14 July, 2012
Turning Astronomy into Business Clusters
Astronomy is big business. South Africa, allied with eight other African countries, is planning to build the world’s most powerful radio telescope - an instrument 50-100 times more sensitive and 10,000 times faster than any radio imaging telescope ever built.
More than 70 institutes in 20 countries, together with industry partners such as Intel, are participating in the scientific and technical design.
This science to business project is truly of global significance and a potential opportunity for ESOF delegates. The design, construction and operation of the telescope will have a potentially global impact on skills development in science, engineering and associated industries.